Santen links with Singapore institute for new ophthalmics

14 November 2014

Japanese mid-size ophthalmic drugmaker Santen Pharmaceutical (TYO: 4536) and the Singapore Eye Research Institute (SERI) have launched a strategic, multi-year collaboration designed to develop new therapeutics in ophthalmology by bringing together the two parties' capabilities in ophthalmic R&D, with a special focus on diseases prevalent in Asia.

Several key programs were established in which substantial synergy can be found between Santen's asset portfolio and longstanding drug development program, and SERI's novel technologies and proven translational research capabilities. R&D activities will span a variety of domains within ophthalmology and involve high level researchers from both sides, with the goal of establishing a robust pipeline of therapeutics which Santen will be able to bring to market and to benefit patients.

Key driver to strengthen Santen R&D capabilities

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK